Findings: WEIGHT LOSS IN ADOLESCENTS The STEP TEENS study detailed below evaluated the effects of Wegovy on weight loss in obese adolescents aged 12 - 17 years RCT STEP TEENS Study - Wegovy vs Placebo for Weight Loss in Obese Adolescents, NEJM (2022) [PubMed abstract] The STEP TEENS study enrolled 201 obese adolescents aged 12 - 17 years Main inclusion criteria Age 12 to 10% Baseline characteristics Average age 15.4 years Female sex - 62% Average weight - 238 lbs (108 kg) Average BMI - 37 Randomized treatment groups Group 1 (134 patients): Wegovy 2.4 mg once weekly Group 2 (67 patients): Placebo Before treatment, all patients underwent a 12-week run-in phase where they received lifestyle interventions Wegovy was started at 0.25 mg once weekly and titrated to 2.4 mg over 16 weeks Percentage change in BMI from baseline to week 68 Primary outcome: Results Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone Findings: Summary Wegovy caused impressive weight loss in the STEP TEENS study, and its effects were greater than other drugs approved for adolescent obesity (see Qsymia and Saxenda)
some request additional documentation
PlexusDx compounded semaglutide injection therapy works across all 50 states without insurance requirements or membership fees, with HSA/FSA eligibility available
This under-eye solution is your all-in-one answer to achieving a refreshed and vibrant gaze, supporting a smoother, firmer, and more luminous eye area without the use of harsh ingredients
I think we need to be more prepared, theres going to be more breakouts, we had a very rough respiratory season, this last year, everybody I knew was sick, I got sick, even though I had my flu vaccine, and I had my COVID vaccine, I didnt have flu, nor COVID, it was something else
DNA Cell Biol 31:13491355 Aoyama K, Nakaki T (2013) Impaired glutathione synthesis in neurodegeneration
.webp)
